These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 16472600)

  • 1. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
    Fickert P; Wagner M; Marschall HU; Fuchsbichler A; Zollner G; Tsybrovskyy O; Zatloukal K; Liu J; Waalkes MP; Cover C; Denk H; Hofmann AF; Jaeschke H; Trauner M
    Gastroenterology; 2006 Feb; 130(2):465-81. PubMed ID: 16472600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
    Stiehl A; Rudolph G; Sauer P; Theilmann L
    J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
    Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
    Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.
    Halilbasic E; Fiorotto R; Fickert P; Marschall HU; Moustafa T; Spirli C; Fuchsbichler A; Gumhold J; Silbert D; Zatloukal K; Langner C; Maitra U; Denk H; Hofmann AF; Strazzabosco M; Trauner M
    Hepatology; 2009 Jun; 49(6):1972-81. PubMed ID: 19475687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice.
    Wagner M; Halilbasic E; Marschall HU; Zollner G; Fickert P; Langner C; Zatloukal K; Denk H; Trauner M
    Hepatology; 2005 Aug; 42(2):420-30. PubMed ID: 15986414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis.
    Rudolph G; Endele R; Senn M; Stiehl A
    Hepatology; 1993 Jun; 17(6):1028-32. PubMed ID: 8514251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
    Fickert P; Fuchsbichler A; Wagner M; Zollner G; Kaser A; Tilg H; Krause R; Lammert F; Langner C; Zatloukal K; Marschall HU; Denk H; Trauner M
    Gastroenterology; 2004 Jul; 127(1):261-74. PubMed ID: 15236191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
    Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
    Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes.
    Popov Y; Patsenker E; Fickert P; Trauner M; Schuppan D
    J Hepatol; 2005 Dec; 43(6):1045-54. PubMed ID: 16223543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis.
    Mair M; Zollner G; Schneller D; Musteanu M; Fickert P; Gumhold J; Schuster C; Fuchsbichler A; Bilban M; Tauber S; Esterbauer H; Kenner L; Poli V; Blaas L; Kornfeld JW; Casanova E; Mikulits W; Trauner M; Eferl R
    Gastroenterology; 2010 Jun; 138(7):2499-508. PubMed ID: 20193684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bile duct proliferation associated with bile salt-induced hypercholeresis in Mdr2 P-glycoprotein-deficient mice.
    Hulzebos CV; Voshol PJ; Wolters H; Kruit JK; Ottenhof R; Groen AK; Stellaard F; Verkade HJ; Kuipers F
    Liver Int; 2005 Jun; 25(3):604-12. PubMed ID: 15910498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice.
    Miethke AG; Zhang W; Simmons J; Taylor AE; Shi T; Shanmukhappa SK; Karns R; White S; Jegga AG; Lages CS; Nkinin S; Keller BT; Setchell KD
    Hepatology; 2016 Feb; 63(2):512-23. PubMed ID: 26172874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.
    Olsson R; Boberg KM; de Muckadell OS; Lindgren S; Hultcrantz R; Folvik G; Bell H; Gangsøy-Kristiansen M; Matre J; Rydning A; Wikman O; Danielsson A; Sandberg-Gertzén H; Ung KA; Eriksson A; Lööf L; Prytz H; Marschall HU; Broomé U
    Gastroenterology; 2005 Nov; 129(5):1464-72. PubMed ID: 16285948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
    Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
    J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporary resolution of obstructive jaundice during ursodeoxycholic acid therapy in a patient with primary sclerosing cholangitis and a dominant biliary stricture.
    Fracchia M; Soubrane O; Houssin D; Galatola G
    Ital J Gastroenterol; 1995; 27(8):430-5. PubMed ID: 8775469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
    Reich M; Spomer L; Klindt C; Fuchs K; Stindt J; Deutschmann K; Höhne J; Liaskou E; Hov JR; Karlsen TH; Beuers U; Verheij J; Ferreira-Gonzalez S; Hirschfield G; Forbes SJ; Schramm C; Esposito I; Nierhoff D; Fickert P; Fuchs CD; Trauner M; García-Beccaria M; Gabernet G; Nahnsen S; Mallm JP; Vogel M; Schoonjans K; Lautwein T; Köhrer K; Häussinger D; Luedde T; Heikenwalder M; Keitel V
    J Hepatol; 2021 Sep; 75(3):634-646. PubMed ID: 33872692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2
    Meng F; Kennedy L; Hargrove L; Demieville J; Jones H; Madeka T; Karstens A; Chappell K; Alpini G; Sybenga A; Invernizzi P; Bernuzzi F; DeMorrow S; Francis H
    Lab Invest; 2018 Nov; 98(11):1465-1477. PubMed ID: 30143751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.
    Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Weiglein AH; Lammert F; Marschall HU; Tsybrovskyy O; Zatloukal K; Denk H; Trauner M
    Gastroenterology; 2002 Oct; 123(4):1238-51. PubMed ID: 12360485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies.
    Trauner M; Halilbasic E; Kazemi-Shirazi L; Kienbacher C; Staufer K; Traussnigg S; Hofer H
    Dig Dis; 2014; 32(5):631-6. PubMed ID: 25034298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary sclerosing cholangitis.
    Zein CO; Lindor KD
    Semin Gastrointest Dis; 2001 Apr; 12(2):103-12. PubMed ID: 11352117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.